Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended ...

Bio-Rad Laboratories, Inc. ( BIO) Q4 2025 Earnings Call February 12, 2026 5:00 PM EST Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this ...

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Bio-Rad Laboratories Inc (BIO) reports a 3.9% sales increase in Q4 2025, driven by diagnostics growth, despite supply chain and market headwinds.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announces it has received validation from AOAC International for its ...

PCR is a well-established technique, and over the past decade, it has been adapted to quantify RNA and DNA quicker and more accurately. Multiplex PCR technologies have been developed to increase the ...

The global HLA typing market is expected to expand at a compound annual growth rate (CAGR) of approximately 6% during the ...

PASADENA, Calif., Feb. 9, 2026 /PRNewswire/ -- Bidding opens on February 11 in a major Tiger Group biopharma-industry auction of new and late-model GMP Manufacturing and Quality Control Laboratory ...

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

Droplet Digital TM PCR (ddPCR TM) has been an evolving tool for precision and absolute detection in genomics for over a ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.

Increase in prevalence of genetic disorders, shift towards personalized medicine, and surge in demand for forensic DNA analysis are the major factors which drive the global genotyping market growth.